Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 2/20 | 0.41 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658927 | 0.82 | CNR1 (0.45) | EDNRBEDNRACHRM1ALDH1A1SCN9A | |
| SCHEMBL5660005 | 0.81 | ALDH1A1 (0.40) | ALDH1A1SCN9ATP53MAPT | |
| SCHEMBL5661475 | 0.79 | CNR1 (0.38) | ALDH1A1SCN9ATP53TSHRCNR1 | |
| SCHEMBL14457605 | 0.75 | TP53 (0.54) | ALDH1A1SCN9ATP53TSHRHTT | |
| SCHEMBL5658451 | 0.74 | SCN9A (0.54) | ALDH1A1SCN9ATP53 | |
| SCHEMBL5660576 | 0.74 | MAPT (0.35) | ALDH1A1SCN9ATSHRHTTCNR1 | |
| SCHEMBL5660474 | 0.72 | PDE4A (0.35) | ALDH1A1HTT | |
| SCHEMBL6625714 | 0.71 | NR3C2 (0.33) | CNR1GPR55MAPT | |
| SCHEMBL14457581 | 0.69 | SCN9A (0.51) | EDNRBEDNRAALDH1A1SCN9ATP53 | |
| SCHEMBL5660790 | 0.69 | SCN9A (0.30) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | EDNRB 337/4885EDNRA 216/4885CHRM1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.